Sign inJoin waitlistJoin the waitlist

Maureen O'Brien

Visiting Professor of Pediatrics, Section of Hematology, Oncology & Bone Marrow Transplantation · University of Colorado School of Medicine

Credentials: · · · · · ·

History

University of Colorado School of Medicine
Present

Pediatric Hematology-Oncology
2003–2004
Pediatrics
2000–2003
Harvard Medical School
1996–2000

Research

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Journal of Clinical Oncology · 2016 · 488 citations
Health-related quality of life as a predictor of mortality following coronary artery bypass graft surgery. Participants of the Department of Veterans Affairs Cooperative Study…
JAMA · 1999 · 356 citations
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children
New England Journal of Medicine · 2025 · 187 citations

Christine Phillips
7 papers
Erin Breese
7 papers
FG
Frederick Grover
7 papers
Gulshan Sethi
7 papers
Jennifer McNeer
7 papers
Jeremy Rubinstein
7 papers · 2 as a fellow
Mignon Loh
7 papers
Susan Rheingold
7 papers
John Perentesis
6 papers
Rachel Rau
6 papers
TM
Tamara Miller
6 papers
Benjamin Mizukawa
5 papers

Grants

Pediatric Acute Lymphoblastic Leukemia: Improving Outcomes Through Incorporation of Novel Targeted Therapies into Treatment for Relapsed and Newly Diagnosed Disease
National Cancer Institute · R50
Contact PI · $516K · University of Colorado Denver
2024–2029
Processes Predictive of Cabg Complications
Agency for Healthcare Research and Quality · R03
Contact PI · $32.4K · University of Colorado Denver
2000–2002

Clinical trials

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Principal investigator · Active not recruiting · Phase 2
Children's Oncology Group
2017–2026
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Principal investigator · Completed · Phase 1
Epizyme, Inc.
2014–2016
Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma
Principal investigator · Terminated · Early phase 1
Children's Hospital Medical Center, Cincinnati
2012–2017